https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0r=
CyBv9bezcPT-2BuItTLKIHepbxTbo-2FYbVFPSBekB-2Bmk9X7Kl8shoTE6BsSbYYjHYcOVCrOC=
rjYrJUHPDVbu1NKaBE-3D-PEb_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2=
FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLN=
n-2B6FohpNoV33LRaEyf0mqf17xp6pekr8So7QYtu3-2FdIMO4RVZQjZ5My948U2-2B61xp-2Fx=
iQJcKqqFG5y07R6jIoVvlZB3RVDVoYHP-2BVdj0ta3CQoVZmkFE7n-2FVUVHjdkS5qE6Qmc5-2F=
je09XTRCfpmv80fvszVsX6vJfl0SPPYJhyFtdsEi74HCHCNVv4a07HTCtJbzIsbsPeCsmD3XaFF=
Jzhxnbb-2BwEkhReOi9-2B-2FnSbpMSyr2YKx83ZVk-3D
** UCB=E2=80=99s General Meeting of Shareholders 2024
------------------------------------------------------------
=C2=B7 For financial year 2023: Gross dividend of =E2=82=AC 1.36 per share =
(+ 2,26%), payable 30 May 2024
=C2=B7 All agenda items put to vote approved
=C2=B7 UCB=E2=80=99s Board of Directors composed by a majority of independe=
nt directors=C2=A0
=C2=B7 The message of Jean-Christophe Tellier, CEO of UCB is available on U=
CB=E2=80=99s global corporate website
Brussels (Belgium), 25 April 2024 =E2=80=93 18:00 (CEST) (regulated informa=
tion) =E2=80=93 Today, UCB held its Annual General Meeting of Shareholders =
(AGM) directly followed by an Extraordinary General Meeting of the Sharehol=
ders (EGM). The Company offered the choice to UCB shareholders to either pa=
rticipate in-person or to cast their vote by proxy. At the AGM [154 502 563=
] shares (81,11% of shares entitled to vote) were represented. At the EGM, =
[152.708.839] shares were represented (80,17% of shares entitled to vote).
The message of Mr. Jean-Christophe Tellier, Chief Executive Officer of UCB,=
published at the occasion of this general meeting, is available on the UCB=
website (https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo=
7XKIuSly0rC2gh0pAj0jRFBrcUOJMNg4G4Or8ULqxfOhO2qoHb5I5NfNpL7tQOe1oo63P9y4Wua=
ruvoRNtLMkewApLQxCO-2BWafwjw39nycKZ2k9TGDYbrN8_Uj_2dCLUNbuBjhX746-2FvM63L9H=
yn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO9=
3DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33LRaEyf0mqf17xp6pekr8So7QYtu3-2FdIMO4R=
VZQjZ5My948U2-2B61xp-2FxiQJcKqqFG5y07R6jIoVvlZB3RVDVoYHYRpQHU7Fatbad0bW3HP3=
na18WL87tFln-2B4XHMFK5leTAyRcRaj-2Be3reWGSk-2BawJKqPnyqVtUqsmLOdNpnGjueTP5h=
L4IqJDtF8t7UistX4OIwTbobLiQ7ppvDLmH8VoaQZmEgxY0geX-2FUSXhHt3E0-3D .
During his speech, Mr. Tellier commented: =E2=80=9CToday, I=E2=80=99m pleas=
ed to stand in front of you and talk about the unique new phase we=E2=80=99=
ve begun. With 14 major regulatory approvals for UCB medicines across six p=
atient populations and three continents, we are now able to provide more, n=
ew and differentiated treatment options for people living with severe disea=
ses.=E2=80=9D During his speech, Jean-Christophe Tellier also spoke about t=
he company=E2=80=99s bright future: =E2=80=9CUCB is poised for a decade plu=
s of growth, driven by our dedicated employees and commitment to creating v=
alue for patients and society. Looking ahead, we're confident in our five g=
rowth drivers: EVENITY^=C2=AE, FINTEPLA^=C2=AE=E2=96=BC, BIMZELX^=C2=AE, RY=
STIGGO^=C2=AE, and ZILBRYSQ^=C2=AE. These medicines, coupled with our robus=
t innovation efforts, form the backbone of our growth strategy.=E2=80=9D=C2=
=A0
The AGM approved for the fiscal year 2023 the payment of a gross dividend o=
f =E2=82=AC 1.36 per share (net dividend of =E2=82=AC 0.952 per share) comp=
ared to =E2=82=AC 1.33 per share for 2022 (net =E2=82=AC 0.931). The ex-div=
idend date is 26 April 2024, the dividend (coupon no. 27) will be payable a=
s of 30 April 2024.
During the AGM, three Board mandates renewals were approved: (i) the mandat=
es of Pierre Gurdjian and Ulf Wiinberg were renewed as independent director=
s for a term of 4 years and they will both continue to be members of the Go=
vernance, Nomination and Compensation Committee (GNCC). (ii) the mandate of=
Charles-Antoine Janssen was also renewed as director for a term of 4 years=
and he will continue to be a member of the GNCC too. He has also replaced =
Fiona du Monceau as Vice-Chair of the Board, as she stepped down from the B=
oard to take on an Executive Committee role within UCB. During the AGM, Mrs=
. Fiona was thanked for her contribution to the Board which illustrated her=
dedication to people and society, her leadership and strong business acume=
n.=C2=A0
Bert De Graeve stepped down from the Board of Directors of UCB at the occas=
ion of this AGM. after a 14-year service in the Board of UCB. During his sp=
eech, Jean-Christophe Tellier expressed his deepest appreciation for Bert D=
e Graeve=E2=80=99s remarkable service and invaluable contributions during h=
is tenure on the Board.
The Annual General Meeting of UCB also approved the appointment of the foll=
owing 3 new independent Board Members, each one for a term of 4 years: (i) =
Nefertiti Greene, also joining the GNCC (ii) Dolca Thomas, becoming member =
of the Scientific Committee and (iii) Rodolfo Savitzky, also becoming membe=
r and chair of the Audit Committee. =C2=A0
UCB=E2=80=99s Board of Director continues to be composed of a majority of i=
ndependent directors (10 out of 14 members or 71% independent members, in c=
omparison to 54% at 31 December 2023). The Audit Committee and the Governan=
ce, Nomination and Compensation Committee will be chaired by independent di=
rectors, respectively Rodolfo Savitzky and Kay Davies. From a gender divers=
ity perspective, the Board will be composed of 6 women and 8 men (43% in co=
mparison to 38% at 31 December 2023).
For the curriculum vitae of the Board members, please visit the UCB website=
: https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly=
0rC2gh0pAj0jRFBrcUOJMNg4E0IunWKPW1RKzxxbPvyYwu4-2BGROe9nsSDxTo8-2FUU7ZDg-3D=
-3DUcu-_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ=
0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33LRaE=
yf0mqf17xp6pekr8So7QYtu3-2FdIMO4RVZQjZ5My948U2-2B61xp-2FxiQJcKqqFG5y07R6jIo=
VvlZB3RVDVoYPVQix-2B6tdD1h-2BY-2B99IUtJjwB6ursXhLIYDSE0HSZwwBlqGucJrbTxtXdC=
ss3g-2F9vTan65x79U9gR0EnPeINyFWlfF-2Bi8YXhxlx6SH1VvGEH-2FND27xVwAECUwis6vAk=
p6iJ1RZGlq7-2FrOUt72QuewXk-3D (https://u7061146.ct.sendgrid.net/ls/click?up=
n=3Du001.gqh-2BaxUzlo7XKIuSly0rC2gh0pAj0jRFBrcUOJMNg4E0IunWKPW1RKzxxbPvyYwu=
Dh9cEwZ6z77lyFQcnlayVg-3D-3D-CFi_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCj=
ZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33Sbk=
EZvEGLNn-2B6FohpNoV33LRaEyf0mqf17xp6pekr8So7QYtu3-2FdIMO4RVZQjZ5My948U2-2B6=
1xp-2FxiQJcKqqFG5y07R6jIoVvlZB3RVDVoYM0PnEK2S4XCUKhXVsey3ERhz3fxFWlDKrg-2F9=
A3QnaKUjuITsswvIoTVYUodxowAnONGsVIR6WpXHwF4Y2fRwOvhm0LU-2BzssNTJ9-2FwIxRAUH=
Wd8VS-2BYyaec-2BC-2BubrnCHFNQfCBuQsXilv66YeGwKNhM-3D .=C2=A0
All other agenda items put to vote at the AGM and EGM were approved by the =
shareholders. More information including details of the votes will be avail=
able soon on UCB's website (https://u7061146.ct.sendgrid.net/ls/click?upn=
=3Du001.gqh-2BaxUzlo7XKIuSly0rC2gh0pAj0jRFBrcUOJMNg4G4Or8ULqxfOhO2qoHb5I5Nf=
NpL7tQOe1oo63P9y4WuavfjbzuJLFRB7lq0CIfxhlcxfOQILOjI-2FfdGxbcnfWxEYJFy_2dCLU=
NbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6=
ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33LRaEyf0mqf17xp6pe=
kr8So7QYtu3-2FdIMO4RVZQjZ5My948U2-2B61xp-2FxiQJcKqqFG5y07R6jIoVvlZB3RVDVoYG=
kr4mKP2r-2FRoUsNK5-2B0TE1wenE6ukvqkCh-2BYYePw5ZiNW4Waid3Xmy3I2HeN-2FG3UcgDY=
SQsxeOq-2F9EDsUxBDzf1-2Fau8M3v-2BxE-2F9GUZ4daT3dfuf-2FBKQ81akbWM8pMP1Aak8r1=
CeUaNyBuy1Kg37ntQ-3D .
The Integrated Annual Report 2023 of UCB can be downloaded on UCB's website=
at https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuS=
ly0rC2gh0pAj0jRFBrcUOJMNg4FZAZJZrp83BD0VGJjVPkMQT2oy8rWcWZHGz0c-2BYa5XXw-3D=
-3DVerN_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ=
0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33LRaE=
yf0mqf17xp6pekr8So7QYtu3-2FdIMO4RVZQjZ5My948U2-2B61xp-2FxiQJcKqqFG5y07R6jIo=
VvlZB3RVDVoYO8dgKcX33By-2BkTjWO6astuek9kc2T759THerIs0gi4hV1uGqc80M-2B17CZHI=
ZU0FwitBj-2BJxkV52X8yNzpG8wrRvosMFwmHWOUZ7cQ-2FAcEee6LAR-2FhrMs9QM-2B4rbNUw=
zzORqZoeWZS7rxzPWhNLQ7So-3D or is available on the online portal at https:/=
/u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCz9eqdO=
Vgsosw7ayZf6jIINTtG4Aij-2F0-2BZ7d0fUCtDT53cyv_2dCLUNbuBjhX746-2FvM63L9Hyn3K=
nTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93Dwf=
Ixs8cV3s33SbkEZvEGLNn-2B6FohpNoV33LRaEyf0mqf17xp6pekr8So7QYtu3-2FdIMO4RVZQj=
Z5My948U2-2B61xp-2FxiQJcKqqFG5y07R6jIoVvlZB3RVDVoYBK6RMdACCydI12mnL8o-2Ff8I=
N8hXSZL2dm1OdAlZ7vNrcsmyTBQIk7vF5xr-2B9uIIL6NAOxz7n8V8t29eHBPMK-2BqvrzhbYuE=
yDuABGzp-2FRZORxEujRw3ujsF3IiBwPbPvgS-2FyMbtNDbMpd74ZgyZtcIw-3D
The financial results for the first half year 2024 will be published on 25 =
July 2024.=C2=A0
Next year's General Meeting will be held on 24 April 2025.
For further information, contact UCB:=C2=A0
Investor Relations
Antje Witte
Investor Relations, UCB
T +32.2.559.9414
Global Communications=C2=A0
Laurent Schots
Media Relations, UCB
T+32.2.559.9264
Laurent.schots@ucb.com=C2=A0
About UCB=C2=A0
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 9,000 peopl=
e in approximately 40 countries, the company generated revenue of =E2=82=AC=
5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Foll=
ow us on Twitter: @UCB_news.
Forward looking statement
This document contains forward-looking statements, including, without limit=
ation, statements containing the words =E2=80=9Cpotential=E2=80=9D, =E2=80=
=9Cbelieves=E2=80=9D, =E2=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=
=9D, =E2=80=9Cintends=E2=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=
=80=9D, =E2=80=9Cestimates=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=
=E2=80=9D, =E2=80=9Ccontinue=E2=80=9D and similar expressions. These forwar=
d-looking statements are based on current plans, estimates and beliefs of m=
anagement. All statements, other than statements of historical facts, are s=
tatements that could be deemed forward-looking statements, including estima=
tes of revenues, operating margins, capital expenditures, cash, other finan=
cial information, expected legal, arbitration, political, regulatory or cli=
nical results or practices and other such estimates and results. By their n=
ature, such forward-looking statements are not guaranteeing future performa=
nce and are subject to known and unknown risks, uncertainties, and assumpti=
ons which might cause the actual results, financial condition, performance =
or achievements of UCB, or industry results, to be materially different fro=
m any future results, performance, or achievements expressed or implied by =
such forward-looking statements contained in this document.=C2=A0
Important factors that could result in such differences include but are not=
limited to: global spread and impacts of wars and pandemics, changes in ge=
neral economic, business and competitive conditions, the inability to obtai=
n necessary regulatory approvals or to obtain them on acceptable terms or w=
ithin expected timing, costs associated with research and development, chan=
ges in the prospects for products in the pipeline or under development by U=
CB, effects of future judicial decisions or governmental investigations, sa=
fety, quality, data integrity or manufacturing issues; potential or actual =
data security and data privacy breaches, or disruptions of our information =
technology systems, product liability claims, challenges to patent protecti=
on for products or product candidates, competition from other products incl=
uding biosimilars, changes in laws or regulations, exchange rate fluctuatio=
ns, changes or uncertainties in tax laws or the administration of such laws=
, and hiring and retention of its employees. There is no guarantee that new=
product candidates will be discovered or identified in the pipeline, or th=
at new indications for existing products will be developed and approved. Mo=
vement from concept to commercial product is uncertain; preclinical results=
do not guarantee safety and efficacy of product candidates in humans. So f=
ar, the complexity of the human body cannot be reproduced in computer model=
s, cell culture systems or animal models. The length of the timing to compl=
ete clinical trials and to get regulatory approval for product marketing ha=
s varied in the past and UCB expects similar unpredictability going forward=
. Products or potential products which are the subject of partnerships, joi=
nt ventures or licensing collaborations may be subject to disputes between =
the partners or may prove to be not as safe, effective or commercially succ=
essful as UCB may have believed at the start of such partnership. UCB=E2=80=
=99s efforts to acquire other products or companies and to integrate the op=
erations of such acquired companies may not be as successful as UCB may hav=
e believed at the moment of acquisition. Also, UCB or others could discover=
safety, side effects or manufacturing problems with its products and/or de=
vices after they are marketed. The discovery of significant problems with a=
product similar to one of UCB=E2=80=99s products that implicate an entire =
class of products may have a material adverse effect on sales of the entire=
class of affected products. Moreover, sales may be impacted by internation=
al and domestic trends toward managed care and health care cost containment=
, including pricing pressure, political and public scrutiny, customer and p=
rescriber patterns or practices, and the reimbursement policies imposed by =
third-party payers as well as legislation affecting biopharmaceutical prici=
ng and reimbursement activities and outcomes. Finally, a breakdown, cyberat=
tack or information security breach could compromise the confidentiality, i=
ntegrity and availability of UCB=E2=80=99s data and systems.
Given these uncertainties, you are cautioned not to place any undue relianc=
e on such forward-looking statements. These forward-looking statements are =
made only as of the date of this document, and do not reflect any potential=
impacts from the evolving conflicts, wars, pandemics, as well as any other=
adversity, unless indicated otherwise. The company continues to follow the=
development diligently to assess the financial significance of these event=
s, as the case may be, to UCB.
UCB expressly disclaims any obligation or duty to update any forward-lookin=
g statements in this document, either to confirm the actual results or to r=
eport or reflect any change in its forward-looking statements with regard t=
hereto or any change in events, conditions or circumstances on which any su=
ch statement is based, unless such statement is required pursuant to applic=
able laws and regulations.
GenericFile
UCB PR Update April 25 2024 ENG (https://u7061146.ct.sendgrid.net/ls/click?=
upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepZ6lk3CbPEPYgc1Z7ks=
7yN3WjloHRwv5-2FsMP4lIFWPJrEc5Oms9kWO9Wclb-2FoHnFQ0-3DHAZG_2dCLUNbuBjhX746-=
2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia=
3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33LRaEyf0mqf17xp6pekr8So7QYtu3=
-2FdIMO4RVZQjZ5My948U2-2B61xp-2FxiQJcKqqFG5y07R6jIoVvlZB3RVDVoYFmTo5yFU2LXX=
udzVjF8rB-2BIRUpvh4-2F8hJiOSnzQKfkxZbiEZ4AGPvBTEjxIr6-2FtJxoNCFQDhyJMquEGEM=
BC4xwyTfhWQNcv3EM9-2BPx0kdSwrMQimMElHNafAU-2BKRcmg3rWozJUc5kXU55rRexF0Cgg-3=
D
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIu=
Sly0rC3nfmD42E6tJ6HwHGmqtXbhtXDlQ2cTEdRpWV-2BrYPIUNgMNpCQqqGiIX7zJUK-2FHLZN=
2gg1x64-2B0eeWqj8fP7aol3DP04WSGF8AQH66zeg0-2BOIPGdRLh8KJrTGd9-2BXIQvnZGd6EH=
xapBYCeFIFsmnYPI-3DBQfg_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FK=
l1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-=
2B6FohpNoV33LRaEyf0mqf17xp6pekr8So7QYtu3-2FdIMO4RVZQjZ5My948U2-2B61xp-2FxiQ=
JcKqqFG5y07R6jIoVvlZB3RVDVoYOHnYUmjxELnM1yaga3yhlTa7JtzGSjbTmJUKvkYXJYo1gpU=
DfpxrlZlnERCpDfITzdZm08rN0-2FODiA2DxwBsB0h8dWGdZW-2BIa9MMFb3woEpGdnzNkAtdpf=
9SWlD9FFrO65AEivzfnDv-2Fk-2B9zhc4ZNA-3D
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium
